NC-DOLE-FOOD-NC
16.4.2020 21:32:09 CEST | Business Wire | Press release
Dole Food Company announced today that in an effort to help with the COVID-19 crisis, Dole and its associated growers have so far donated more than two million pounds of fresh produce to recipients along its supply chain, from local food banks in the U.S. to the communities in Latin America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200416005885/en/
“The virus is ruthless, and we have seen the brutal impact it has had on people—directly to their health and their income,” stated Johan Linden, CEO of Dole Food Company. “We want to answer the needs of the communities around our operations and do what we can to strengthen them during this moment of hardship.”
Dole recognizes these donations alone will not solve the food needs issue brought on by the coronavirus, but believes that we should all do what we can to help those around us. Dole is committed to continuing these efforts during this crisis.
Vince Hall, CEO of Feeding San Diego, an organization whose mission is to connect every person facing hunger with nutritious meals, shared his comments on Dole’s actions.
“While medical providers and first responders battle the COVID-19 crisis, Feeding San Diego is battling unprecedented hunger across San Diego County. One of our most important allies in this fight is Dole Food Company, a significant employer at the Port of San Diego. Dole continues to regularly donate large amounts of nutritious fresh fruit, especially bananas, which are very popular in the community and contribute to good health. Dole is to be commended for helping Feeding San Diego take care of those in need all year round, but especially during the current health crisis.”
In addition to San Diego, Dole has made donations in other U.S. cities including New York, Philadelphia, Charlotte, Houston, Los Angeles.
In Latin America, where Dole grows its tropical fruits, such as bananas and pineapple, the crisis is also hitting hard, and the company is supporting those rural communities where food security is most at risk. In the Aguan Valley of Honduras, for example, in addition to fruit Dole is distributing household staples such as rice, beans and cooking oil to employees and local communities. Beyond food, the company is also providing masks, sanitizing gel, testing kits and other health supporting supplies. Similar support is happening for communities in Costa Rica, Ecuador, Guatemala and Colombia including the provision of over 15,000 personal hygiene kits to aid in the prevention of infection.
“As an important local employer, it is our duty to support local communities. The consequences of this crisis are just starting to be felt here and the need for social support will continue to be felt in the weeks and months to come,” stated Renato Acuña, President of Dole Fresh Fruit Latin America. “Our local foundations and those of our associated producers are actively working on the ground and on the front line of this crisis, and Dole will provide additional support as long as necessary.”
The Dale Foundation, funded by Dole and its Ecuadorian growers, is using its medical staff and facilities to get the word out to the community on the importance of COVID-19 prevention, identifying high risk citizens to help them undertake the proper care, advancing purchases of medication that can help with respiratory illness, and continuing to operate its health clinics and provide remote medical services for its patients in the agricultural community.
Dole is also supporting those working on the front lines of the crisis by donating to hospitals in various countries where it operates and working with civil authorities to provide local aid.
For example, in the U.S., Dole has joined national produce distributor PRO*ACT, and other produce partners, to bring fresh produce to the tables of healthcare workers and their families during the COVID-19 crisis. The ‘Feeding our Frontlines’ program (www.producepartners.org ) provides boxes of fresh produce for healthcare employees to take home at the end of a long shift as a way of saying “thank you” to those taking care of us."
About Dole Food Company
Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200416005885/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom